Blackfynn Announces Collaboration with The Michael J. Fox Foundation to Build a Neurodegenerative Disease Data Ecosystem

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on March 21, U.S. local time, Blackfynn, a biotechnology company based in Philadelphia, Pennsylvania, announced collaborations with multiple institutions to establish a data ecosystem for neurodegenerative diseases and leverage its novel data integration and analytics platform to accelerate the development of therapies for neurological disorders.

Reportedly, Blackfynn’s partners in this initiative include the Michael J. Fox Foundation (MJFF) and the University of Rochester. In addition, neurologist Dr. Karl Kieburtz will join the Blackfynn team as the company’s Head of Clinical R&D.

Dr. Karl Kieburtz is a neurologist specializing in movement disorders, the principal investigator for more than 50 clinical studies on movement disorders, and a member of 15 FDA Data Monitoring Committees. Dr. Kieburtz will lead Blackfynn’s Parkinson’s Progression Markers Initiative (PPMI), helping the company establish a world-leading clinical database for neurodegenerative diseases.

Blackfynn, founded in 2015, is a data-driven life sciences company dedicated to transforming the diagnosis and treatment of neurological disorders. The company integrates and comprehensively analyzes patient data, clinical data, biospecimens, pathological information, and other relevant datasets. Through data integration and research, it seeks to identify data-driven scientific therapies for curing neurological disorders.

Approximately 1 billion people worldwide are affected by epilepsy, Parkinson’s disease (PD), Alzheimer’s disease (AD), and other neurodegenerative disorders, for which there are currently no scientifically proven curative therapies. Blackfynn hosts the Fox Insight study, sponsored by its partner, The Michael J. Fox Foundation. This study has enrolled more than 30,000 patients with Parkinson’s disease (PD) and, through comparative analysis with data from healthy controls, aims to elucidate disease progression and identify potential risk factors contributing to PD. The project was launched last October when Blackfynn first partnered with The Michael J. Fox Foundation, with Blackfynn leading the PPMI initiative.

The University of Rochester is also a core member of the PPMI. Blackfynn collaborates with Dr. Charles Venuto at the University of Rochester to develop models for neurodegenerative diseases and identify biomarkers from extensive clinical data. Most candidate drugs developed for neurological disorders have ended in failure. Through repeated trials, it has become evident that identifying biomarkers within disease mechanisms, as well as determining disease subtypes and progression risks, are critical components of clinical drug development. To date, the University of Rochester has conducted over one hundred clinical trials and has identified more than ten drug candidates for the treatment of neurological diseases and movement disorders.

“There is currently no unified database for neurodegenerative diseases,” said Dr. Amanda Christini, President of Blackfynn. “There is phenotypic overlap among certain neurodegenerative disorders, allowing their shared mechanisms to be identified as drug targets. Blackfynn is collaborating with partners to build a database focused on neurodegenerative diseases, accelerating the discovery of biomarkers.”

Dr. Karl Kieburtz added, “By leveraging its proprietary data platform, Blackfynn can extract new insights from complex data, thereby paving the way for novel therapies for neurological disorders.”

The Michael J. Fox Foundation, established in 2000, is a trust fund headquartered in New York. The foundation is dedicated to finding better therapies to cure Parkinson’s disease and funds companies engaged in Parkinson’s research to support their clinical development and commercial operations.

(Compiled by: Wang Chan)